


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**

**45 RESEARCH RESULTS WILL BE PRESENTED AT 2025 ASCO ANNUAL MEETING  
(INCLUDING 12 ORAL SESSIONS)**

The board of directors (the “**Board**”) of the Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group will present 45 latest research results, among which, 12 sessions will be oral sessions and 4 sessions will be Late-Breaking Abstract (LBA), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

**12 ORAL SESSIONS**

**1. Abstract Number: LBA8502**

CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC): a randomized, single-blind, multicenter phase 3 study.

Session Type: Oral (LBA)

Corresponding Author: Baohui Han, Shanghai Chest Hospital

First Author: Baohui Han, Shanghai Chest Hospital

**2. Abstract Number: 8514**

Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).

Session Type: Rapid Oral

Corresponding Author: Yuankai Shi, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital

First Author: Yuankai Shi, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital

**3. Abstract Number: LBA8004**

R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy.

Session Type: Oral (LBA)

Corresponding Author: Ming Chen, Sun Yat-sen University Cancer Center

First Author: Ming Chen, Sun Yat-sen University Cancer Center

**4. Abstract Number: LBA3502**

Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).

Session Type: Oral (LBA)

Corresponding Author: Ke-Feng Ding, The Second Affiliated Hospital, Zhejiang University School of Medicine

First Author: Ke-Feng Ding, The Second Affiliated Hospital, Zhejiang University School of Medicine

**5. Abstract Number: LBA2000**

Efficacy and safety of STUPP regimen with or without anlotinib for newly diagnosed glioblastoma: Results of a multicenter, double-blind, randomized phase II trial.

Session Type: Oral (LBA)

Corresponding Author: Zhongping Chen, Sun Yat-Sen University Cancer Center

First Author: Yuanyuan Chen, Sun Yat-Sen University Cancer Center

**6. Abstract Number: 11501**

Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma (STS): A randomized, double-blind, parallel-controlled, phase III study.

Session Type: Oral

Corresponding Author: Yuhong Zhou, Zhongshan Hospital, Fudan University; Xiaohui Niu, Beijing Jishuitan Hospital

First Author: Yuhong Zhou, Zhongshan Hospital, Fudan University

**7. Abstract Number: 5508**

Benmelstobart plus carboplatin/paclitaxel with or without anlotinib, followed by maintenance benmelstobart with or without anlotinib, as first-line treatment for advanced or recurrent endometrial cancer: A randomized, open-label, phase II trial.

Session Type: Oral

Corresponding Author: Xiaojun Chen, Shanghai Tenth People's Hospital

First Author: Xiaojun Chen, Shanghai Tenth People's Hospital

**8. Abstract Number: 3003**

Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial.

Session Type: Oral

Corresponding Author: Rui-Hua Xu, Shusen Wang, University Cancer Center State Key Laboratory of Oncology in South China

First Author: Rui-Hua Xu, Shusen Wang, University Cancer Center State Key Laboratory of Oncology in South China

**9. Abstract Number: 11502**

Eribulin plus anlotinib in advanced soft tissue sarcoma (ERAS): Updates on efficacy and biomarkers.

Session Type: Oral

Corresponding Author: Yu Jiang, West China Hospital, Sichuan University

First Author: Jie Liu, West China Hospital, Sichuan University

**10. Abstract Number: 11506**

A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).

Session Type: Oral

Corresponding Author: Robin Jones, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research

First Author: Robin Jones, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research

## **11. Abstract Number: 4010**

Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies.

Session Type: Oral (Clinical Science Symposium)

Corresponding Author: Lin Shen, Peking University Cancer Hospital and Institute

First Author: Jifang Gong, Peking University Cancer Hospital and Institute

## **12. Abstract Number: 6011**

REMATCH2201: A phase II study on reducing surgical margins in HPV-negative advanced HNSCC with neoadjuvant PD-1 inhibitor and AP chemotherapy.

Session Type: Oral (Clinical Science Symposium)

Corresponding Author: Kunyu Yang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

First Author: Kunyu Yang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

## **OTHER SESSION TYPES**

### **Lung Cancers**

#### **1. Abstract Number: 8600**

A retrospective study of anlotinib plus third-generation EGFR-TKIs in advanced non-small cell lung cancer with gradual or oligo progression after EGFR-TKIs treatment (ALTER-L058).

Session Type: Poster

Corresponding Author: Caicun Zhou, Shanghai East Hospital, Tongji University

First Author: Caicun Zhou, Shanghai East Hospital, Tongji University

**2. Abstract Number: 8043**

Safety and efficacy of radiotherapy combined with anlotinib in locally advanced non-small cell lung cancer patients intolerant to concurrent chemoradiotherapy: Preliminary result of a phase II clinical trial.

Session Type: Poster

Corresponding Author: Jianyang Wang, Cancer Hospital Chinese Academy of Medical Sciences

First Author: Yupei Yuan, Cancer Hospital Chinese Academy of Medical Sciences

**3. Abstract Number: 8063**

Neoadjuvant hypofractionated radiotherapy plus tislelizumab with anlotinib followed by adjuvant tislelizumab with anlotinib in patients with resectable non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial (NEO-PIONEER).

Session Type: Poster

Corresponding Author: Jian Ceng, Yongling Ji, Zhejiang Cancer Hospital (Zhejiang Cancer Center)

First Author: Min Fang, Zhejiang Cancer Hospital (Zhejiang Cancer Center)

**Digestive system tumors**

**4. Abstract Number: 4159**

TQB2868 combined with anlotinib and nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.

Session Type: Poster

Corresponding Author: Xianjun Yu, Fudan University Shanghai Cancer Center; Xiaobing Chen, Henan Cancer Hospital

First Author: Si Shi, Fudan University Shanghai Cancer Center

**5. Abstract Number: 3026**

First in human phase I study of TQB2103, a Claudin18.2 (CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Session Type: Poster

Corresponding Author: Xiangdong Cheng, Zhejiang Cancer Hospital

First Author: Xiangdong Cheng, Zhejiang Cancer Hospital

**6. Abstract Number: e16110**

Updated results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective exploratory study.

Session Type: Publication

Corresponding Author: Baosheng Li, Shandong Cancer Hospital and Institute

First Author: Xin Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital

**7. Abstract Number: e16225**

FAITH trial: Feasibility and safety of anlotinib plus benmelstobart in patients with previously immunotherapy treated intermediate-to-advanced hepatocellular carcinoma – A multicenter, single arm, prospective phase II trial.

Session Type: Publication

Corresponding Author: Hui-Chuan Sun, Zhongshan Hospital affiliated with Fudan University

First Author: Yinghao Shen, Zhongshan Hospital affiliated with Fudan University

**8. Abstract Number: e16195**

Preliminary results of anlotinib and penpulimab (anti-PD1) combined with GEMOX in first-line treatment of advanced biliary tract cancer: A single-center, single-arm exploratory study.

Session Type: Publication

Corresponding Author: Mei Guan, Peking Union Medical College Hospital

First Author: Zhiyang Zhang, Peking Union Medical College Hospital

**9. Abstract Number: e16394**

Tislelizumab with anlotinib and chemotherapy for second-line treatment of pancreatic ductal adenocarcinoma: A phase II clinical trial.

Session Type: Publication

Corresponding Author: Yinying Wu, First Affiliated Hospital of Medical College of Xi'an Jiaotong University

First Author: Xuyuan Dong, First Affiliated Hospital of Medical College of Xi'an Jiaotong University

**10. Abstract Number: e16224**

Updated results of anlotinib plus benmelstobart combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.

Session Type: Publication

Corresponding Author: Hong Zong, The First Affiliated Hospital of Zhengzhou University

First Author: Shui-Ling Jin, The First Affiliated Hospital of Zhengzhou University



**11. Abstract Number: e16385**

Efficacy and safety of second-line therapy by envafolimab combined with anlotinib and S-1 in pancreatic cancer patients: A single-arm, phase II clinical trial.

Session Type: Publication

Corresponding Author: Mei Zhang, The First Affiliated Hospital of Anhui Medical University

First Author: Zhifa Zhu, The First Affiliated Hospital of Anhui Medical University

**12. Abstract Number: TPS4228**

ALTER-PA001: A multicenter, randomized study of anlotinib and benmelstobart in combination with AG chemotherapy vs. AG as first-line treatment for metastatic pancreatic cancer.

Session Type: Poster

Corresponding Author: Liwei Wang, Shanghai Jiao Tong University School of Medicine

First Author: Jiujiu Cui, Shanghai Jiao Tong University School of Medicine

**Breast cancers**

**13. Abstract Number: 1104**

ETER901: A randomized, open-label, phase III trial of anlotinib in combination with anti-PD-L1 antibody benmelstobart (TQB2450) versus nab-paclitaxel in first-line treatment of recurrent or metastatic triple-negative breast cancer.

Session Type: Poster

Corresponding Author: Binghe Xu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital

First Author: Jiayu Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital

**14. Abstract Number: 591**

Efficacy and safety of neoadjuvant TQB2102 in women with locally advanced or early HER2-positive breast cancer: A randomized, open-label, multi-centre phase 2 trial.

Session Type: Poster

Corresponding Author: Zhiming Shao, Fudan University Shanghai Cancer Center

First Author: Junjie Li, Fudan University Shanghai Cancer Center

**15. Abstract Number: 1090**

Preliminary efficacy and safety of TQB2102 in patients with HER2 low-expressing recurrent/metastatic breast cancer: Results from a phase 1b study.

Session Type: Poster

Corresponding Author: Shusen Wang, Sun Yat-Sen University Cancer Center; Qingyuan Zhang, Harbin Medical University Cancer Hospital

First Author: Shusen Wang, Sun Yat-Sen University Cancer Center

**16. Abstract Number: 1033**

Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with  $\geq 2$  line treatments: Results from a phase 1b/2 study.

Session Type: Poster

Corresponding Author: Qingyuan Zhang, Harbin Medical University Cancer Hospital

First Author: Qingyuan Zhang, Harbin Medical University Cancer Hospital

**17. Abstract Number: 588**

Neoadjuvant penpulimab combined with taxanes and carboplatin in triple-negative breast cancer: A single-arm, open-label, multi-center phase II clinical study (neoTAPPL).

Session Type: Poster

Corresponding Author: Xiaowei Qi, Southwest Hospital, Army Medical University

First Author: Wenting Yan, Southwest Hospital, Army Medical University

**18. Abstract Number: e13059**

A new option for post-CDK4/6is resistance era: Multicenter real-world study of anlotinib-based combination therapy in hormone receptor-positive metastatic breast cancer resistant to CDK4/6 inhibitors.

Session Type: Publication

Corresponding Author: Quchang Ouyang, Hunan Cancer Hospital

First Author: Binliang Liu, Hunan Cancer Hospital

**19. Abstract Number: e12600**

The preliminary efficacy and safety results of neoadjuvant phase II study of anlotinib plus tislelizumab combined with chemotherapy in triple-negative breast cancer.

Session Type: Publication

Corresponding Author: Jing Luo, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

First Author: Jing Luo, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

## Gynecologic Cancers

### 20. Abstract Number: 5527

A phase II study of anlotinib plus penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Results from ALTER-GO-020 trial.

Session Type: Poster

Corresponding Author: Guonan Zhang, Sichuan Cancer Hospital and Institute

First Author: Dengfeng Wang, Sichuan Cancer Hospital and Institute

## Head and neck cancers

### 21. Abstract Number: 6096

Efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced differentiated thyroid cancer (DTC): A multicenter, single-arm, phase II study.

Session Type: Poster

Corresponding Author: Ming Gao, Tianjin Union Medical Center

First Author: Dapeng Li, Tianjin Medical University Cancer Institute and Hospital

### 22. Abstract Number: 6031

Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.

Session Type: Poster

Corresponding Author: Jun Ma, Qingqing Cai, Sun Yat-sen University Cancer Center

First Author: Cheng Xu, Sun Yat-sen University Cancer Center

**23. Abstract Number: e18098**

A phase II clinical study of neoadjuvant penpulimab combined with chemotherapy for patients with locoregionally advanced, resectable squamous cell carcinoma of the head and neck.

Session Type: Publication

Corresponding Author: Chenping Zhang, Min Ruan, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

First Author: Nannan Han, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

**24. Abstract Number: e18133**

Efficacy and safety of anlotinib combined with <sup>131</sup>I therapy in the treatment of distant metastatic differentiated thyroid cancer: A single-arm, phase II clinical study.

Session Type: Publication

Corresponding Author: Dong Dai, Tianjin Cancer Hospital Airport Hospital

First Author: Dong Dai, Tianjin Cancer Hospital Airport Hospital

**Urinary system cancers**

**25. Abstract Number: 4536**

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma: Subgroup analysis from the phase 3 ETER100 trial.

Session Type: Poster

Corresponding Author: Jun Guo, Peking University Cancer Hospital & Institute; Aiping Zhou, Cancer Hospital Chinese Academy of Medical Sciences

First Author: Xinan Sheng, Peking University Cancer Hospital & Institute

**26. Abstract Number: 4525**

Anlotinib plus everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma: 1 year updated results from UC-001, a single-center, single-arm, phase II trial.

Session Type: Poster

Corresponding Author: Hailiang Zhang, Dingwei Ye, Fudan University Shanghai Cancer Center

First Author: Wen-Hao Xu, Fudan University Shanghai Cancer Center

**27. Abstract Number: 4526**

Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Preliminary results from an exploratory prospective multicentre clinical study.

Session Type: Poster

Corresponding Author: Fangjian Zhou, Sun Yat-Sen University Cancer Center

First Author: Pei Dong, Sun Yat-Sen University Cancer Center

**Bone tumors**

**28. Abstract Number: e23507**

Preliminary results of anlotinib combined with gemcitabine and docetaxel for recurrent or metastatic primary malignant bone tumors: An open-label, single-arm, multicenter clinical trial.

Session Type: Publication

Corresponding Author: Jingnan Shen, First Affiliated Hospital, Sun Yat-Sen University

First Author: Yiyang Bian, First Affiliated Hospital, Sun Yat-Sen University

## Other tumors

### 29. Abstract Number: 3108

An open-label phase 1 dose-escalation and dose-expansion trial to evaluate the safety, tolerability, and efficacy of TQ-B3234 in adults with neurofibromatosis type 1 (NF1).

Session Type: Poster

Corresponding Author: Qingfeng Li, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

First Author: Jun Liu, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

## Neutropenia

### 30. Abstract Number: e24100

Guard-01: A prospective study of efbemalenograstim alfa as primary prophylaxis for concurrent chemo-radiotherapy induced neutropenia.

Session Type: Publication

Corresponding Author: Ming Chen, Sun Yat-Sen University Cancer Center

First Author: Yuanyuan Chen, Sun Yat-Sen University Cancer Center

### 31. Abstract Number: e24088

Guard-02: Safety and efficacy of prophylactic use of novel long-acting G-CSF efbemalenograstim  $\alpha$  on same-day of chemotherapy in breast cancer patients.

Session Type: Publication

Corresponding Author: Yueyin Pan, Anhui Provincial Cancer Hospital

First Author: Shoubing Zhou, Anhui Provincial Cancer Hospital

**32. Abstract Number: e20560**

Efbemalenograstim alfa for the primary/secondary prophylaxis of intermediate-risk febrile neutropenia (FN) chemotherapy regimen with risk factors in patients with non-small cell lung cancer (NSCLC): A randomized, multicenter, exploratory clinical trial.

Session Type: Publication

Corresponding Author: Dingzhi Huang, Tianjin Medical University Cancer Institute and Hospital

First Author: Mengjie Li, Tianjin Medical University Cancer Institute and Hospital

**33. Abstract Number: e17566**

Efbemalenograstim alfa for primary prophylaxis of chemotherapy-induced neutropenia in patients with ovarian and cervical cancer: A single-arm, multicenter clinical trial.

Session Type: Publication

Corresponding Author: Beihua Kong, Qilu Hospital of Shandong University

First Author: Limei Wang, Qilu Hospital of Shandong University

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 24 April 2025

*As of the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*